Article Per Year (5 Year)
p-Index From 2019 - 2024
0.444
P-Index
This Author published in this journals
All Journal Qanun Medika - Medical Journal Faculty of Medicine Muhammadiyah Surabaya Jurnal Insan Farmasi Indonesia
Ferdias Kurnia Bahari
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology Physics

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
ANALISIS EFEKTIFITAS-BIAYA ANTARA KOMBINASI SALBUTAMOL-IPRATROPIUM DENGAN SALBUTAMOL PADA SERANGAN ASMA Amelia Lorensia; Ferdias Kurnia Bahari
Jurnal Insan Farmasi Indonesia Vol 3 No 1 (2020): Jurnal Insan Farmasi Indonesia
Publisher : Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36387/jifi.v3i1.470

Abstract

Treatment of asthma exacerbation is necessary to get attention to get effective and efficient treatment. The first line of treatment for asthma exacerbation is nebulation salbutamol, but some asthma treatments require additional combinations of ipratropium. know the cost-effectiveness with the use of a combination of salbutamol and ipratropium bromide with salbutamol alone to improve asthma symptoms and length of treatment in patients with asthma attacks. The study design was retrospective from medical record data of asthma patients in a hospital in Surabaya in the period from January-October 2017. Dependent variables were cost and clinical outcome (duration of treatment and loss of breathless symptoms). Data analysis used was ACER calculation and different test. The subjects were 64 people, consisting of 23 people in group A (salbutamol-ipratropium) and 41 people in group B (salbutamol). Group A was more cost-effective in length of treatment and trade-off in reducing asthma symptoms than in group B. There was no significant difference between costs (p(0.816)> 0.05), length of treatment (p=0.386)> 0.05)) and improvement of asthma symptoms (p (0.676)> 0.05). Therefore, further research was needed on the level o f other asthma attacks and other cost/outcome components.
Roflumilast: A Review of Chronic Obstructive Pulmonary Disease (COPD) Treatment Ita Octafia; Dwi Octamy Sari; Novi Wulandari; Sandra Annisa; Linda Wahyuni Wongkar; Ferdias Kurnia Bahari; Faiz Farikhah; Moh Firmansah; Erfin Midhiawati; Fauna Herawati
Qanun Medika - Jurnal Kedokteran FK UMSurabaya Vol 5, No 1 (2021)
Publisher : Universitas Muhammadiyah Surabaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30651/jqm.v5i1.5043

Abstract

Abstract Chronic Obstructive Pulmonary Disease (COPD) is a chronic airway inflammation with resulting progressive airflow limitation that has a high incidence, morbidity, and mortality. Roflumilast is an oral phosphodiesterase-4 inhibitor as a therapy to decrease the risk of COPD exacerbations in patients with moderate-severe COPD with a history of chronic bronchitis. Roflumilast can be given orally once daily as a single or combination drug. It can be used as COPD moderate-severe but also more beneficial as COPD mild treatment. The efficacy of Roflumilast can prevent exacerbations of repetition and can fixed lung function both in terms of FEV1 and vital capacity to force. The incidence of side effects, which are diarrhea and digestive disorders. The cost-effectiveness showed that Quality of life patient with Roflumilast is better than the group without additional. This paper aimed to review systematically Roflumilast as COPD treatment for the clinical application.Keywords                   : COPD, Roflumilast, phosphodiesterase-4 inhibitorCorrespondence          : fauna@staff.ubaya.ac.id
Co-Authors Amelia Lorensia Anak Agung Gede Sugianthara Dwi Octamy Sari Erfin Midhiawati Faiz Farikhah Fauna Herawati Ita Octafia Linda Wahyuni Wongkar Moh Firmansah Sandra Annisa